The International Generic and Biosimilars Medicines Association (IGBA), which represents generic and biosimilar medicines associations worldwide, recently released its report on how trade agreements can foster generic and biosimilar medicines and improve patient access to care.
The International Generic and Biosimilars Medicines Association (IGBA), which represents generic and biosimilar medicines associations worldwide, recently released its report on how trade agreements can foster generic and biosimilar medicines and improve patient access to care.
“While trade agreements should be focused on facilitating trade between countries, all too often we see agreements that erect new barriers to the trade for generic and biosimilar medicines manufacturers and hinder access to affordable medicines” said Jim Keon, chair of IGBA and its international trade and intellectual property committee, in a statement. “The removal of such barriers would reduce costs for the development of generic and biosimilar medicines and ensure that such products can be traded freely and enter markets without delay,” he added.
In the report, IGBA says that it “strongly supports the rules-based multilateral trading system, which ensures that international trade is conducted on the basis of the rule of law and due process,” sets out its priorities for generics and biosimilars in trade agreements.
First, IGBA calls for greater transparency in legislative and regulatory processes for product, as well as greater regulatory convergence of requirements related to product approval. The organization voices its support for conditions that will allow generics—particularly complex generics—to be developed in single programs, and it supports convergence among requirements for assessment for generics to reduce development costs. Guidelines issued by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use can serve as a basis for domestic legislation.
With respect to biosimilars, IGBA notes that some regulators are moving toward allowing the use of foreign comparator products, “which should also increasingly waive the requirement for bridging data in certain instances.” The organization said that trade agreements could require frameworks that allow global development programs for biosimilars and convergence of data requirements for approval.
IGBA also calls for trade agreements to build on and further develop collaborative approaches to good manufacturing practice, and to avoid duplication of inspections.
The organization raises concerns about intellectual property provisions in trade agreements; bilateral rather than multilateral negotiations can lead to the creation of new standards for intellectual property that could alter the balance between encouraging investment and ensuring competition. Therefore, provisions on patentability of inventions, says IGBA, should reflect the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs Agreement).
Patent linkage mechanisms—under which approval for a generic cannot be granted until patents on the originator are expired or declared invalid—should be avoided in trade agreements. On the other hand, regulatory review clauses, which allow generic and biosimilar makers to use patented inventions for the purposes of developing information that will help them later gain regulatory approval, should be mandatory.
Data exclusivity, says IGBA, is not mandated by the TRIPs Agreement, and interpretations of the agreement used to introduce data exclusivity requirements into trade agreements should be rejected; agreements should not contain provisions related to data exclusivity that extend beyond TIRPs requirements. Additionally, IGBA opposes inclusion of requirements leading to longer market exclusivity period for biologics.
In cases in which some countries can grant extended patent terms, such as through a supplementary protection certificate, generic and biosimilar developers should be allowed to export their products during the term of extended protection. Patents should not be subject to measures such as criminal enforcement.
Finally, IGBA also has concerns about abusive intellectual property-related practices, and it says that it will gladly engage with negotiators to provide detailed information on how treaty language can safeguard against abuses.
Lastly, incentives for biosimilars and generics are also of concern for the organization, and the report states that countries where patent linkage exists and where data protection is high particularly need clear frameworks for incentives.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.